Climb Bio, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Climb Bio, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($12.89M) | Nov 6, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($8.67M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($8.67M) | Aug 12, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($20.78M) | Nov 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($20.78M) | May 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($20.78M) | Aug 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($8.90M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($54.89M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($54.89M) | Nov 6, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($1.70M) | May 14, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($1.70M) | Nov 6, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($1.70M) | Aug 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($3.97M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($5.22M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($22.29M) | May 15, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($9.68M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($14.60M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($13.20M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($9.62M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($8.72M) | Aug 15, 2022 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($14.89M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($10.68M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($23.02M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($11.73M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($56.37M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.01M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($5.00M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($6.71M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($23.44M) | May 15, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($8.75M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($13.70M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($13.13M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($9.38M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($8.71M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($6.88M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($2.26M) | Nov 8, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($1.61M) | Sep 13, 2021 |